Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
4900 Results for "
conjugates
" in MedChemExpress (MCE) Product Catalog:
Products (4900)
4900 Results for "conjugates" in MCE Product Catalog:
116
116 Publications Verification
Referencia número: HY-19696B
No. CAS: 117609-50-4
Synonyms: Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate
103
103 Cited Publications
Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
Áreas de investigación:
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
63
63 Cited Publications
Synonyms: MMAE; SGD-1010
Target:
Áreas de investigación:
Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
36
36 Cited Publications
Synonyms: MC-GGFG-DXD
Target:
Áreas de investigación:
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
30
30 Cited Publications
Referencia número: HY-19792
No. CAS: 139504-50-0
Synonyms: DM1; Maytansinoid DM1
Target:
Áreas de investigación:
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
21
Category:
Human Gut Microbiota Metabolites Other disease Disease markers Metabolic Disease Microorganism Endogenous metabolite Disease Research Fields Steroids
Target:
21
Target:
19
19 Cited Publications
Referencia número: HY-N0324B
No. CAS: 206986-87-0
Category:
Target:
14
14 Cited Publications
Synonyms: AzBTS-(NH4)2
14
14 Cited Publications
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Target:
Áreas de investigación:
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
14
14 Cited Publications
Synonyms: Exatecan derivative for ADC
Target:
Áreas de investigación:
DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
14
14 Cited Publications
Synonyms: T-DXd; DS-8201; DS-8201a
Target:
Áreas de investigación:
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Note: The product sizes indicate only the active ingredient of ADC. For information about the excipients in this product, please refer to the COA.
13
13 Cited Publications
Synonyms: DM1-SMCC
Target:
Áreas de investigación:
SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC) .
12
12 Cited Publications
Synonyms: IMMU-132
Target:
Áreas de investigación:
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
12
12 Cited Publications
Synonyms: IMMU-132 (solution)
Target:
Áreas de investigación:
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
12
12 Cited Publications
Synonyms: N-(3-Azidopropyl)biotinamide
11
11 Cited Publications
Referencia número: HY-42973
No. CAS: 1353016-71-3
Target:
Áreas de investigación:
DBCO-NHS ester is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-NHS ester is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
10
10 Cited Publications
Synonyms: CMX001; HDP-CDV
Target:
Áreas de investigación:
Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo .
10
Target:
Áreas de investigación:
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
9
9 Cited Publications
Synonyms: Monomethylauristatin F hydrochloride
Target:
Áreas de investigación:
MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
